Pertuzumab, Trastuzumab, and Docetaxel for HER2-Positive Breast Cancer
| Autor: | J. Aubrey Waddell, Rose M. Cheng, Dominic A. Solimando |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Pharmacology
medicine.medical_specialty Cancer chemotherapy business.industry Pharmacist Pharmacy 03 medical and health sciences 0302 clinical medicine Docetaxel Trastuzumab 030220 oncology & carcinogenesis Family medicine HER2 Positive Breast Cancer medicine Pharmacology (medical) Pharmacy practice 030212 general & internal medicine Pertuzumab business medicine.drug |
| Zdroj: | Hospital Pharmacy. 51:35-38 |
| ISSN: | 1945-1253 0018-5787 |
| DOI: | 10.1310/hpj5101-35 |
| Popis: | *Dr. Cheng is a PGY1 Pharmacy Practice Resident at Blount Memorial Hospital, Maryville, Tennessee. The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|